TCR2 Therapeutics Inc
F:2K7
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
T
|
TCR2 Therapeutics Inc
F:2K7
|
US |
|
Agf A/S
CSE:AGF B
|
DK |
|
W
|
Wuxi Honghui New Materials Technology Co Ltd
SZSE:002802
|
CN |
|
Chemometec A/S
F:CHY
|
DK |
|
Intermediate Capital Group PLC
LSE:ICP
|
UK |
|
BASF India Ltd
NSE:BASF
|
IN |
|
Lancashire Holdings Ltd
LSE:LRE
|
BM |
|
NIU Technologies
NASDAQ:NIU
|
CN |
|
C
|
China Resources Beverage Holdings Co Ltd
HKEX:2460
|
CN |
|
Blackbaud Inc
NASDAQ:BLKB
|
US |
|
Z
|
Zhibao Technology Inc
NASDAQ:ZBAO
|
CN |
|
YIT Oyj
LSE:0GKA
|
FI |
|
T
|
Titan Kogyo Ltd
TSE:4098
|
JP |
|
Regen BioPharma Inc
OTC:RGBP
|
US |
TCR2 Therapeutics Inc
TCR2 Therapeutics, Inc. is a clinical-stage cell therapy company, which engages in the development of biological drugs and engineering T-cells for cancer therapy. The company is headquartered in Cambridge, Massachusetts and currently employs 137 full-time employees. The company went IPO on 2019-02-14. The firm's T cell receptor (TCR) Fusion Construct T cells (TRuC-T cells) specifically recognize and kill cancer cells by harnessing the entire T cell receptor (TCR) signaling complex. Its lead TRuC-T cell, which targets solid tumors is gavocabtagene autoleucel (gavo-cel). The firm is conducting Phase I/II clinical trial for gavo-cel to treat patients with non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma and cholangiocarcinoma. Its other product candidates include TC-510, GPC3 and IL-15, which focuses on solid tumors, and CD70, which focuses on renal cell carcinoma. Its TC-510 is a TRuC-T cell targeting mesothelin-expressing solid tumors which incorporates a PD-1:CD28 chimeric switch receptor.
TCR2 Therapeutics, Inc. is a clinical-stage cell therapy company, which engages in the development of biological drugs and engineering T-cells for cancer therapy. The company is headquartered in Cambridge, Massachusetts and currently employs 137 full-time employees. The company went IPO on 2019-02-14. The firm's T cell receptor (TCR) Fusion Construct T cells (TRuC-T cells) specifically recognize and kill cancer cells by harnessing the entire T cell receptor (TCR) signaling complex. Its lead TRuC-T cell, which targets solid tumors is gavocabtagene autoleucel (gavo-cel). The firm is conducting Phase I/II clinical trial for gavo-cel to treat patients with non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma and cholangiocarcinoma. Its other product candidates include TC-510, GPC3 and IL-15, which focuses on solid tumors, and CD70, which focuses on renal cell carcinoma. Its TC-510 is a TRuC-T cell targeting mesothelin-expressing solid tumors which incorporates a PD-1:CD28 chimeric switch receptor.
